Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies. HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match this unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy. Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Brains for Europe Project is an initiative that comes up from the inside of the educational centres and is conceived as a solid contribution to the ongoing pedagogical renovation both thematically and methodologically. The aim of B4E is the introduction of learning in neurosciences (one of the most promising scientific areas, to which the European Commission is nowadays paying a growing attention) in educational centres, through the creation inside them of neuroscience classrooms that will open a new operative frame which we define as metaschool. Unlike top-down conventional learning, metaschool implies another type of learning, much more horizontal or even bottom-up, led by students of the different centres, in which the very students are those who decide and lead their own learning and – using the suggested tools – help to offer it to the rest of the fellow students of their own centre and to those of the other countries’ centres involved in the project. B4E has got 9 formal partners altogether: 1 foundation (and hospital), 2 companies, 5 educational centres and a mutual insurance company dedicated to education and rehabilitation in disability. Four of the partners are from Spain and the rest belongs to Turkey, Poland, Romania, France and Iceland. The countries involved are therefore 6. One has to add the involvement of 3 non-formal partners: 3 European networks such as NICE Foundation, ENVITER and HIPEN. Among the main activities of the Project, it appears in the first place a teacher training of those who will take part later in the coordination of the neuroscience classrooms (neuromentors). Once constituted a neuroscience classroom, it will be tackled in it different subjects related to the brain, to the relationship between neurosciences and technology, and to the mental disease (the question of education and rehabilitation in disability will be underlined) making the students to get opened, among other things, to the STEM Learning, to the critical thinking, to the learning to learn and to the neurological health. Students’ approach to these subjects will have an active character articulated according to the answers to concrete challenges they are going to be posed. Students will work their materials and will expose them in TED-like talks, that they will share with the rest of participants but also with the rest of the centre’s students through an e-platform. Young people taking part in the Project, among 12 and 16 years old, will get identified with it and with their role as influencers that will become an example and a motivation for the rest of their fellow students. They will be the axis around which our metaschool will spin. The idea of generating a metaschool inside a conventional educational centre, in coordination with it and profiting the channels afforded by new technologies and network communication forms provides an effective pedagogical novelty reinforced at the same time by the matter in question, decisive when it comes to inform the new pedagogical theories on the details of learning. Direct impact of B4E will be performed on 4 ambits: 1) On the directly involved students, that will take part of a different type of education, on which they have the power of decision, founded on their possibility of discovering and on their own intellectual effort, and that gets multiplied immediately through their own projection as Project-disseminators. At the same time, B4E is designed to have a great influence on students’ professional vocations, and particularly on female professional vocations. 2) On the centre’s students in general, to which it will lead to a fascinating ambit of knowledge and to which the Project will also offer a new pedagogical proposal. 3) On the centres that take part, first of all, through their teachers’ staffs, that will exercise a new and relevant pedagogical task that will contribute to offer them new possibilities and perspectives. 4) Project’s diffusion will multiply its impact at the social level, in the different countries and in the EU in general. Among its many long-term benefits, our B4E Project, including in its whole not only the urban reality but also the rural one, offers channels to take advantage of all ambits’ European youth’s talent, regardless of how limited are their opportunities in their concrete regions. That will make the difference to sound out aspects of an European collective intelligence and in the long run the Project could maybe serve as a model for future projects and make that young people can recognise themselves more easily as citizens of the same political union, the European one, reinforcing their European identity. In the end, knowing our brain is the best way of knowing ourselves and the environment we have created. Our project aims to offer the students a frame from which articulate this knowledge and set the creative bases of the very neurosciences’ evolution and of the value of its knowledge applied in the future.

MeMeasurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most frequent acute and chronic leukemias, acute myeloid (AML) and chronic lymphocytic leukemia (CLL), but it has not yet been confirmed as a treatment-guiding biomarker. The RESOLVE Consortium will leverage numerous existing expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients, with the expectation that this affordable, minimally-invasive biomarker can be imminently used to guide the intensity of consolidation therapy, improve quality of life (QoL), and reduce costs. This will be achieved through 1) development of a real-world patient registry and data platform; 2) establishment of standardized, decentralized MRD analysis across Europe; and 3) a randomized, controlled multi-national pragmatic trial based on the hypothesis that treatment intensity can be safely reduced in MRD negative AML/CLL patients, to provide evidence for the clinical, personal and societal impact of MRD-guided therapy. These efforts will be supported by RESOLVE’s participatory research pipeline, which will incorporate input from patients, caregivers, and experts in social sciences and health economics. The real-world nature of the study ensures broadly applicable results for all patients regardless of location, socioeconomic status, gender, sex, disability or ethnicity. The findings will then be effectively communicated and disseminated following open science principles through the medical community for uptake in routine clinical practice. The laboratory, clinical, and patient advocacy infrastructures already in place will support rapid adoption of MFC-based MRD assessment to aid in clinical decision-making. The Consortium’s widespread member organizations will work with policymakers and authorities across the EU to provide access to the test in the national health care systems for all AML and CLL patients. This action is part of the Cancer Mission cluster of projects "Diagnostics and Treatment (diagnostics)".

oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.

In all the EU countries, rehabilitation centres specialised in the support of children with visual impairment have more and more cases of children with central visual disorders and a low vision. Our organisations have already developed methodologies and procedure for the support of children for which the visual impairment is due to a dysfunctioning of the eye, as an organ. When the visual impairement is caused by a cererbral background, the impact for children is totally different for the daily life and compensation means we use usually doesn't work. There are more and more cases and this constat is due to the improvement of medical knowledge, and that we didn't identify before the causes of their visual impairment. This is a real issue for all the rehabilitation organisations in Europe, which want to develop/set up a process of evaluation and support, as a standard for our organisations. Our experience with these children show us that they need to have a specific approach in the comprehension of the impact of their disabilities and in the support modalities to set up. And despite the improvement of scientific knowledge on this question, modalities of support are too often some individual processes, without concertation and very isolated, locally. It is important to work together on the development of a coherent and pluridisciplinary process at EU level. In consequence, the objectives of CVI Project were to gather all the experiences of the partners and to develop a common process and common tools to improve the support of visually impaired children with cerebral visual impairment. The partnership is composed of 8 organisations from Europe and one from Quebec, all are specialists in the rehabilitation of visually impaired people. Among the 9 partners, 5 of them are french speaking (MFAM, IRSAM, CRDV from France, IRSA from Belgium and INLB from Longueuil in Quebec). The 4 other organisations are coming from Spain (2), The Netherlands and Croatia. The partnership has developed : - a protocol of assessment for a pluridisciplinary assessment of central visual disorders, working with different professionals : ophtalmologists, orthoptists, neuropsychologists, working with existing tools already used, and adapted to the group when necessary. - A handbook to give the knowledge of the process, the referral to the tools used, and how it works, with the contents of the tools developed in the project.- A questionnaire for relatives and surrounding of the children to support the assessment of the children. -An individual passport in which could be described simply for the environnement the impact of disorders in the life of the child, and also with a key card, a template layed out in A5 format to know more about the context of the child concerned. - A guide (called training course) to enable the professionals to use in a suitable way the outcomes of the project for the benefit of these children. The impact of this project is very important and the number of professionals concerned by these developments is huge. with difficulty to count approximately this figure, we know that at least in the francophone network (composed of 33 organisations in francophone countries), this is approximately 5000 professionnals concerned near or far by the developments. We can say that the impact is very huge in consideration with also the other EU countries